|Table of Contents|

ER2 protein levels predict tumor-free survival and overall survival after radical gastrectomy for gastric cancer patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 24
Page:
4567-4571
Research Field:
Publishing date:

Info

Title:
ER2 protein levels predict tumor-free survival and overall survival after radical gastrectomy for gastric cancer patients
Author(s):
LYU Jiao1; YUAN Cheng2; ZHAO Hongying1; SHI Ran1; ZHU Mei1
1.Department of Medical Oncology;2.Department of Radiotherapy,Xuzhou Cancer Hospital，Jiangsu Xuzhou 221005,China.
Keywords:
HER2 protein; gastric cancer; radical gastrectomy; tumor-free survival; overall survival
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2023.24.015
Abstract:
Objective:To investigate the value of HER2 expression protein in the evaluation on tumor free and overall survival after radical gastrectomy for gastric cancer patients.Methods:All the patients included in the study were divided into HER2 protein positive group or HER2 protein negative group according to the postoperative HER2 protein pathological examination results,t-test or χ2-test was used to compare the clinicopathological indexes between the two groups.1∶1 propensity matching score method was applied to match the patients with similar propensity scores estimated by Logistic model,and the equilibrium of each clinicopathological feature between the two groups after matching was tested again.Kaplan-Meier survival analysis was performed to compare the postoperative tumor-free survival rate and overall survival rate between the two groups after matching,and Cox regression model was used for sensitivity analysis to verify the value of HER2 protein expression in the evaluation of survival after radical gastrectomy.Results:A total of 354 patients with gastric cancer who underwent radical surgery were included in the study,with an average age of (55.82±11.28)years,including 234 males (66.1%) and 120 females (33.9%),and the 5-year postoperative tumor-free survival rate and overall survival rate were 41.2% and 55.7%,respectively.After matching,the clinicopathological parameters between the two groups were balanced and consistent,with no significant difference.Kaplan-Meier survival analysis showed that the 1-year,3-year and 5-year cumulative tumor-free survival rates postoperatively were significantly higher in patients with HER2 negative gastric cancer than in the patients with HER2 positive gastric cancer after matching(83.4%,58.3%,54.3% vs 71.2%,39.1%,30.8%,P=0.019),and the 1-year,3-year and 5-year cumulative overall survival rates postoperatively were significantly higher in HER2 negative gastric cancer patients than in HER2 positive gastric cancer patients (100%,87.9%,73.4% vs 88.6%,55.6%,51.2%,P=0.035).Cox analysis showed that the risk of postoperative recurrence and metastasis of HER2 positive gastric cancer patients was 2.132 times higher than that of HER2 negative patients (OR:2.132,95%CI:1.524~2.743,P=0.021),and the risk of postoperative death was 1.783 times higher than that of HER2 negative patients (OR:1.783,95%CI:1.136~2.435,P=0.028).Conclusion:HER2 expression protein is an independent predictor of postoperative survival in gastric cancer patients,and HER2 positive gastric cancer patients have a higher risk of postoperative tumor recurrence and metastasis,and a shorter postoperative survival.

References:

［1］ SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2021，71(3):209-249.
［2］ SIEGEL RL,MILLER KD,FUCHS HE,et al.Cancer statistics,2021［J］.CA Cancer J Clin，2021，71(1):7-33.
［3］ 曹毛毛,李贺,孙殿钦,等.2000-2019年中国胃癌流行病学趋势分析［J］.中华消化外科杂志,2021,20(1):102-109. CAO MM,LI H,SUN DQ,et al.Analysis on the epidemiological trend of gastric cancer in China from 2000 to 2019［J］.Chinese Journal of Digestive Surgery,2021,20(1):102-109.
［4］ CHEN QY,XIE JW,ZHONG Q,et al.Safety and efficacy of indocyanine green tracer-guided lymph node dissection during laparoscopic radical gastrectomy in patients with gastric cancer:a randomized clinical trial［J］.JAMA Surg,2020,155(4):300-311.
［5］ SHAH D,BENTREM D.Environmental and genetic risk factors for gastric cancer［J］.J Surg Oncol，2022，125(7):1096-1103.
［6］ 胡慧慧,赵慧晨,金玉茜,等.HER2阳性晚期胃癌HER2靶向治疗现状及新药研究进展［J］.郑州大学学报(医学版),2022,57(06):792-797. HU HH,ZHAO HC,JIN YX,et al.Current situation and new drug research progress of HER2-targeted therapy for HER2-positive advanced gastric cancer ［J］.Journal of Zhengzhou University (Medical Science Edition),2022,57(06):792-797.
［7］ MERIC-BERNSTAM F,JOHNSON AM,DUMBRAVA EEI,et al.Advances in HER2-targeted therapy:novel agents and opportunities beyond breast and gastric cancer［J］.Clin Cancer Res,2019,25(7):2033-2041.
［8］ JANJIGIAN YY,MARON SB,CHATILA WK,et al.First-line pembrolizumab and trastuzumab in HER2-positive oesophageal,gastric,or gastro-oesophageal junction cancer:an open-label,single-arm,phase 2 trial［J］.Lancet Oncol,2020,21(6):821-831.
［9］ 张芮毫,张明.进展期胃癌抗HER2治疗研究进展［J］.医学研究生学报,2022,35(02):218-224. ZHANG RH,ZHANG M.Research progress of anti-HER2 therapy for advanced gastric cancer ［J］.Journal of Postgraduate Medicine,2022,35(02):218-224.
［10］ 吕伟,张淑群,靳耀锋,等.HER-2基因突变在恶性实体瘤中的临床研究进展［J］.现代肿瘤医学，2021，29（23）：4238－4242. LYU W,ZHANG SQ,JIN YF,et al.Progress in clinical research of HER-2 gene mutation in malignant solid tumors［J］.Modern Oncology,2021，29（23）：4238－4242.
［11］ SHITARA K,IWATA H,TAKAHASHI S,et al.Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer:a dose-expansion,phase 1 study［J］.Lancet Oncol,2019,20(6):827-836.
［12］ TAKEGAWA N,NONAGASE Y,YONESAKA K,et al.DS-8201a,a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor,overcomes HER2-positive gastric cancer T-DM1 resistance［J］.Int J Cancer,2017,141(8):1682-1689.
［13］ KANAYAMA K,IMAI H,USUGI E,et al.Association of HER2 gene amplification and tumor progression in early gastric cancer［J］.Virchows Arch,2018,473(5):559-565.
［14］ WANG DS,LIU ZX,LU YX,et al.Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer［J］.Gut,2019,68(7):1152-1161.
［15］ TABERNERO J,HOFF PM,SHEN L,et al.Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB):final analysis of a double-blind,randomised,placebo-controlled phase 3 study［J］.Lancet Oncol,2018,19(10):1372-1384.
［16］ 宋婷婷,刘宁,宋姗爱,等.HER-2基因拷贝数与胃癌病人术后生存关系分析［J］.青岛大学学报(医学版),2023,59(02):179-182. SONG TT,LIU N,SONG SA,et al.Analysis of the relationship between HER-2 gene copy number and postoperative survival in patients with gastric cancer ［J］.Journal of Qingdao University (Med Edition),2023,59(02):179-182.
［17］ YOSHIOKA T,SHIEN K,TAKEDA T,et al.Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells［J］.Cancer Sci,2019,110(8):2549-2557.

Memo

Memo:
江苏省卫生健康委科研项目（编号：Z2022097）；江苏省徐州市卫生健康委科技项目（编号：XWKYHT20200042）；江苏省徐州市科技项目（编号：KC22148）
Last Update: 1900-01-01